Route of administration: Topical For the topical treatment of condylomata acuminata affecting the penis or the external female genitalia.
For the topical treatment of condylomata acuminata affecting the penis or the external female genitalia.
Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Galderma announced that the FDA approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Trifarotene is the first...
LEO Pharma announced positive results of the DELTA 2 trial. DELTA 2 is the second of two pivotal phase III clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
Arcutis Biotherapeutics, Inc. announced that it has commenced pivotal Phase III clinical trials evaluating topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis (AD).
Arcutis Biotherapeutics, Inc. announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase III studies evaluating roflumilast cream (ARQ 151) as a potential topical treatment for plaque psoriasis.
Dipexium Pharmaceuticals, Inc. announced that the OneStep-1 and OneStep-2 Phase III clinical trials of Locilex (pexiganan cream 0.8%) in patients...
Allergan announced that the New Drug Application filing for AGN 199201 (oxymetazoline HCl cream 1.0%) an investigational topical prescription product...